Email this article Clinical manifestations of porphyrin metabolism disorders
- Authors: Pustovoit Y.S1, Karpova IV1, Pivnik AV1, Surin VL1, Lukyanenko AV1, Luchinina Y.A1
-
Affiliations:
- Issue: Vol 78, No 7 (2003)
- Pages: 68-73
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/33380
- ID: 33380
Cite item
Full Text
Abstract
Aim. To characterize patients -with various nosological unities ыо/porphyria in accordance with their
age, clinical symptoms, provoking factors, therapy and outcome.
Material and methods. Patients with acute intermittent porphyria (43), hereditary coproporphyria (8),
variegate porphyria (3), porphyria cutanea tarda (7), hepatoerythropoietic porphyria (1), and hereditary
erythropoietic porphyria (2) were studied. One patient was suspected of porphyria caused by deficiency
of delta-aminolevulenic acid dehydrogenase.
Results. The patients were from the CIS. The overwhelming majority of them were young and middleaged
subjects. Rapid development of the disease and severe neurological symptoms were predominantly
observed in patients with acute forms of porphyria.
Conclusion. Early diagnosis of porphyrin metabolism disorders makes it possible to decrease abruptly the
number of cases leading to severe complications, disability, and fatal outcome. The use of inexpensive
methods of screening of porphyrin metabolism disorders provides a promising approach to solving this
problem. These methods should be used in municipal hospitals. In addition, asymptomatic carriers of defective
gene should be revealed at the preclinical stage using various methods of molecular genetic assay
age, clinical symptoms, provoking factors, therapy and outcome.
Material and methods. Patients with acute intermittent porphyria (43), hereditary coproporphyria (8),
variegate porphyria (3), porphyria cutanea tarda (7), hepatoerythropoietic porphyria (1), and hereditary
erythropoietic porphyria (2) were studied. One patient was suspected of porphyria caused by deficiency
of delta-aminolevulenic acid dehydrogenase.
Results. The patients were from the CIS. The overwhelming majority of them were young and middleaged
subjects. Rapid development of the disease and severe neurological symptoms were predominantly
observed in patients with acute forms of porphyria.
Conclusion. Early diagnosis of porphyrin metabolism disorders makes it possible to decrease abruptly the
number of cases leading to severe complications, disability, and fatal outcome. The use of inexpensive
methods of screening of porphyrin metabolism disorders provides a promising approach to solving this
problem. These methods should be used in municipal hospitals. In addition, asymptomatic carriers of defective
gene should be revealed at the preclinical stage using various methods of molecular genetic assay
Keywords
References
- Пустовойт Я. С., Пивник А. В., Карпова И. В. Клинические проявления и диагностика острых порфирий. Тер. арх. 1999; 71 (7): 76-80.
- Kappas A., Sassa S., Galbraith R. A., Nordmann Y. The porphyrias. In: Scriver С R., Beau det A. L., Sly W. S., Valle D., eds. The metabolic basis of inherited disease. 6"' ed. New York: McGraw-Hill; 1989. 1305-1365.
- Идельсон Л. И. Нарушения порфиринового обмена в клинике внутренних болезней. М.; 1969.
- Mognussen С. R., Levine J. В., Doherty J. M. et al. A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood 1974; 44: 857-868.
- Blake D., Poulos V., Rossi R. Diagnosis of porphyria - recommended methods for peripheral laboratories. Clin. Biochem. Rev. 1992; 13: S2-S25.
- Stein J., Tschudy D. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore) 1970; 49: 1-16.
- Goldberg A. Acute intermittent porphyria: a study of 50 cases. Quart. J. Med. 1959; 110: 183-209.
- Lim H. W., Murphy G. M. The Porphyrias. Clin. Dermatol. 1996; 14: 375-387.
- Thunell S. Porphyrins, porphyrin metabolism and porphyrias. Scand. J. Clin. Lab. Invest. 2000; 60 (7): 509-540.
- Галстян Г. М., Шулутко Е. М., Буланов А. Ю. и др. Нетипичные электролитные нарушения у больных с заболеваниями системы крови. Тер. арх. 2000; 72 (7): 63-67.
- Карпова И. В., Пустовойт Я. С., Пивник А. В. и др. Выявление случая острой порфирий среди пациентов психиатрической клиники. Соц. и клин, психиатр. 2000; 10 (3): 76-78.
- Пивник А. В., Подберезин М. М., Пустовойт Я. С. Острая перемежающаяся порфирия: клиника, диагностика, лечение. Гематол. и перел. крови 1998; (1): 36-43.
- Пустовойт Я. С., Галстян Г. М., Карпова И. В. и др. Клинический полиморфизм острой перемежающейся порфирий у близких родственников. Там же. 1999 (4): 32-36.
- Пустовойт Я. С., Галстян Г. М., Пивник А. В. и др. Случай успешного лечения острой перемежающейся порфирий, протекавшей с тетраплегией и потребовавшей длительной интенсивной терапии. Там же. 1998; (1): 51-62.
- De Siervi A., Mendez М., Parera V. Е. et al. Acute intermittent porphyria: characterization of two novel mutations in the porphobilinogen deaminase gene, one amino acid deletion (453-455 del AGC) and one splicing acceptor site mutation (1VS8-1 G > T). Hum. Mutat. (Online) 1999; 14: 355.
- De Siervi A., Rossetti M. K., Parera V. E. et al. Identification and characterization of hydroxymethylbilane synthase mutation causing acute intermittent porphyria: evidence for an ancestral founder of common G 11IR mutation. Am. J. Med Genet. 1999; 86 (4): 366-375.
- Solis С., Lopez-Echaniz I., Sefarty-Graneda D. et al. Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP). Mol. Med. 1999; 5: 664-671.
- Сурин В. Л., Лукьяненко А. В., Карпова И. В. и др. Три новые мутации в гене порфобилиногендезаминазы, обнаруженные у больных острой перемежающейся порфирией из России. Генетика человека. 2001; 37: 1-8.
Supplementary files
